| Date | Title | Description |
| 07.05.2024 | TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors | Accomplished industry veteran brings deep strategic and operational expertise
DENVER–(BUSINESS WIRE)–May 7, 2024– TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy ... |
| 06.05.2024 | Exagen Announces Campaign for Lupus Awareness Month | CARLSBAD, Calif., May 06, 2024 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a campaign focusing on providers, patie... |
| 30.04.2024 | TriSalus Life Sciences Secures up to $50 Million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives | DENVER–(BUSINESS WIRE)–Apr. 30, 2024– TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced the closing of a debt financing facility for up to $50 million with OrbiMed, a healthcare investment firm. The capital is expected to provide... |
| 30.04.2024 | Truvaga™ Plus Demonstrates Health Benefits in Latest Consumer Study, Paving the Way for Market Expansion | ROCKAWAY, N.J., April 30, 2024 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the results of its most recent Truvaga Plus consumer study ... |
| 30.04.2024 | Neurolenses Proven to Reduce Headache Symptoms | Report highlights the data from the recently published double-masked, randomized Headache Study. Based on the clinical study data, Neurolenses provide a statistically significant improvement in headache symptoms.
Click here to view full cli... |
| 26.04.2024 | Exagen Inc. Announces Changes to the Board of Directors | CARLSBAD, Calif., April 26, 2024 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced changes to the Board of Directors.
Exagen is pleased to announce Scott Kahn, Ph.D. is joining... |
| 16.04.2024 | Neurolens + The Chris Wolfe Podcast | Dr. Chris Wolfe and Davis Corley 6-part podcast series
April 16, 2024 12:04:15 PM by Neurolens Marketing.
Listen to Dr. Christopher Wolfe and Neurolens CEO, Davis Corley in this engaging 6-part podcast as they delve into the groundbreaking ... |
| 08.04.2024 | electroCore Announces the Launch of Truvaga Plus® for General Wellness | ROCKAWAY, N.J., April 08, 2024 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the launch of its direct-to-consumer mobile app-enabled product for general ... |
| 02.04.2024 | electroCore Expands Intellectual Property Portfolio | electroCore Granted Two New U.S. Patents
ROCKAWAY, N.J., April 02, 2024 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue n... |
| 01.04.2024 | TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update | DENVER & SALT LAKE CITY–(BUSINESS WIRE)–Apr. 1, 2024– TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced its financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
“2023... |
| 27.03.2024 | TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting | – New safety and feasibility data from Phase 1/1b PERIO-03 trial for locally advanced pancreatic cancer supports further development of the novel TriSalus Infusion System for therapeutic delivery via retrograde venous delivery –
– A retrosp... |
| 18.03.2024 | Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results | CARLSBAD, Calif., March 18, 2024 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year ended December 31, 2023.
Financial High... |
| 13.03.2024 | electroCore Announces Fourth Quarter and Full Year 2023 Financial Results | Record full year 2023 net sales of $16.0 million increased 87% over $8.6 million for the full year 2022
ROCKAWAY, N.J., March 13, 2024 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a commercial-stage bioelectronic med... |
| 13.03.2024 | Neurolens Strengthens Leadership for Accelerated Growth and Innovation | Coppell, Texas — On a mission to transform eye care, Neurolens is pleased to announce a strategic leadership restructuring to fuel continued growth and innovation. This positions the company for even greater success in the evolving eyecare ... |
| 11.03.2024 | TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results | DENVER–(BUSINESS WIRE)–Mar. 11, 2024– TriSalus Life Sciences® Inc. (Nasdaq: TLSI) announced today that the Company will host a conference call and webcast on April 1, 2024, at 9:00 a.m. ET to discuss financial results for the fourth quarter... |
| 07.03.2024 | TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101... | – Nelitolimod, a class C TLR-9 agonist formerly called SD-101, is the Company’s therapeutic candidate designed to overcome biologic barriers in liver and pancreatic tumors
– Nelitolimod is currently being evaluated in three Phase 1/1b studi... |
| 04.03.2024 | Neurolenses Demonstrate Significant Headache Relief | A double-masked, randomized, cross-over clinical study shows that patients wearing Neurolenses had improved scores on a validated headache questionnaire
Neurolens has announced the results of a double-masked, crossover peer-reviewed publica... |
| 29.02.2024 | TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors | Data published in Current Medical Research and Opinion provide a comparison of the TriNav Infusion System vs. standard drug delivery and show the ability of TriNav to successfully treat sicker, treatment refractory, and higher disease burde... |
| 27.02.2024 | ATEC Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Highlights | CARLSBAD, Calif.–(BUSINESS WIRE)– Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter and full year ended D... |
| 06.02.2024 | electroCore Expands Intellectual Property Portfolio | ROCKAWAY, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to ... |
| 09.01.2024 | electroCore Expands Intellectual Property Portfolio | ROCKAWAY, N.J., Jan. 09, 2024 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to ... |
| 08.01.2024 | ATEC Announces Record Preliminary Revenue Results for 2023 and 2024 Revenue Guidance | CARLSBAD, Calif.–(BUSINESS WIRE)– Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today preliminary revenue results for the fourth quarter and ... |
| 07.01.2024 | Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance | CARLSBAD, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announces select preliminary unaudited financial results for the full year ended December 31, 2023, and ... |
| 26.12.2023 | electroCore Expands Intellectual Property Portfolio | electroCore Granted Two New U.S. Patents |
| 14.12.2023 | TriSalus Life Sciences Announces CMS Reimbursement for the TriNav® Infusion System via Assignment of a New Technology Healthcare Common Procedure Coding System (HCPCS) Code | DENVER–(BUSINESS WIRE)–TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, is pleased to announ... |
| 12.12.2023 | electroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology | ROCKAWAY, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to ... |
| 14.11.2023 | TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update | Completed merger with MedTech Acquisition Corporation (MTAC) and started public trading August 11th |
| 13.11.2023 | Exagen Inc. Reports Strong Third Quarter 2023 Results | SAN DIEGO, California, Nov. 13, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2023. |
| 09.11.2023 | Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers | SAN DIEGO, California, Nov. 09, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Johns Hopkins University jointly announced today the execution of an exclusive license agreement. Exa... |
| 08.11.2023 | electroCore Announces Third Quarter 2023 Financial Results | Record third quarter 2023 net sales of $4.5 million, an increase of approximately 128% over third quarter 2022 |
| 07.11.2023 | TriSalus Life Sciences to Host Third Quarter 2023 Financial Results Conference Call | Call Scheduled for Tuesday, November 14, 2023, at 9:00 a.m. ET |
| 06.11.2023 | ATEC Reports Third Quarter 2023 Financial Results and Raises Full Year 2023 Adjusted EBITDA Guidance | CARLSBAD, Calif.–(BUSINESS WIRE)– Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended September 30, 2... |
| 04.11.2023 | Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications | New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment by enabling performance of the TLR9 agonist, SD-101, in metastatic uveal melanoma, consistent with an earlier presentation fro... |
| 03.11.2023 | TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting | New data from PERIO-03 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment by enabling performance of a TLR9 agonist in pancreatic tumors |
| 31.10.2023 | ATEC Equipped to Support Ramping Surgical Volume With Proceeds From Secondary Offering | Positioned to invest in revenue-generating assets as Company continues to capitalize on industry disruptions |
| 27.10.2023 | ATEC Announces Closing of Public Stock Offering | CARLSBAD, Calif.–(BUSINESS WIRE)– Alphatec Holdings, Inc. (“ATEC”) (NASDAQ: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced the closing of its previously announced underw... |
| 25.10.2023 | TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at SITC Annual Meeting | DENVER–(BUSINESS WIRE)–Oct. 25, 2023– TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today... |
| 24.10.2023 | ATEC Announces Proposed Public Offering of Common Stock | CARLSBAD, Calif.–(BUSINESS WIRE)– Alphatec Holdings, Inc. (“ATEC”) (NASDAQ: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced that it has commenced a proposed underwritten ... |
| 24.10.2023 | ATEC Announces Pricing of Public Offering of Common Stock | CARLSBAD, Calif.–(BUSINESS WIRE)– Alphatec Holdings, Inc. (“ATEC”) (NASDAQ: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced the pricing of an underwritten public offering... |
| 24.10.2023 | Data Highlighting nVNS for Treatment of Gastroparesis Symptoms Presented at American College of Gastroenterology Annual Meeting | Clinical trial suggests nVNS can reduce the use of rescue medications for exacerbations of nausea due to Gastroparesis or Functional Dyspepsia |
| 17.10.2023 | ATEC Enhances Board with Renowned Spine Prowess | Dave Demski appointed to Board of Directors; Keith Valentine appointed Special Advisor to Board of Directors |
| 17.10.2023 | electroCore Announces Two-Year Extension of gammaCore™ Device Listing in the NHS Supply Chain Catalogue | Extension maintains listing through March 17, 2026 |
| 16.10.2023 | ATEC Announces Preliminary Third Quarter 2023 Revenue Results and Raises Full-Year Revenue Guidance | Total revenue of $117.7 to $118.5 million |
| 16.10.2023 | ATEC Advances Lateral Surgery With Launch of Expandable Technology | CARLSBAD, Calif.– (BUSINESS WIRE) — October 16, 2023 — Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that the Company’s commitment to a... |
| 11.10.2023 | electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology | ROCKAWAY, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to ... |
| 10.10.2023 | Data Highlighting Non-Invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute Neurological Injury Presented at 2023 World Stroke Congress | VANQUISH Clinical Trial (n=40) suggests safety and efficacy of nVNS for the Treatment of Headache Associated with Subarachnoid Hemorrhage (SAH) |
| 09.10.2023 | ATEC Clinical Precision and Predictability on Display at NASS 2023 | Unleashing 100% spine focus to set the standard in spine care |
| 28.09.2023 | Neurolens Introduces N3 | An immersive, virtual-reality-based measurement and education experience |
| 27.09.2023 | gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Attention and Working Memory in Patients with Post Traumatic Stress Disorder (PTSD) | Two prospective, peer-reviewed trials demonstrate the symptomatic benefit of gammaCore in patients with PTSD |
| 26.09.2023 | electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology | ROCKAWAY, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to... |
| 06.09.2023 | TriSalus Life Sciences Appoints Jodi Devlin as President of TriSalus Therapeutics | Devlin Brings Significant Expertise in Commercialization, Sales and Marketing |
| 10.08.2023 | TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation | DENVER & FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–Aug. 10, 2023– TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients ... |
| 09.08.2023 | electroCore Announces Second Quarter 2023 Financial Results | Record second quarter 2023 net sales of $3.6 million, an increase of approximately 65% over second quarter 2022 |
| 07.08.2023 | Exagen Inc. Reports Strong Second Quarter 2023 Results | SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2023. |
| 03.08.2023 | ATEC Reports Second Quarter 2023 Financial Results and Raises Full Year 2023 Revenue and Adjusted EBITDA Guidance | CARLSBAD, Calif.–(BUSINESS WIRE)– Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended June 30, 2023, ... |
| 31.07.2023 | electroCore, Inc. Announces $8.145 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules | ROCKAWAY, N.J., July 31, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced that it has agreed to issue and sell to cert... |
| 25.07.2023 | gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Improves Attention and Memory in Patients with Posttraumatic Stress Disorder (PTSD) | ROCKAWAY, N.J., July 25, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a peer reviewed manuscript, Effect of Transcutaneous Cervi... |
| 24.07.2023 | Exagen Inc. Appoints Paul Kim to Board of Directors | SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Paul Kim has been appointed as a member of the Exagen Board of Directors, effective July 24, 202... |
| 18.07.2023 | electroCore Expands Intellectual Patent Portfolio for nVNS Technology | ROCKAWAY, N.J., July 18, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office (USPTO) has issued a patent rel... |
| 13.07.2023 | electroCore, Inc. Announces Distribution Agreement with Reliefband Technologies, LLC | ROCKAWAY, N.J., July 13, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that ReletexTM by Reliefband, the first and only FDA cleared non-invasive neu... |
| 11.07.2023 | electroCore Provides Select Second Quarter 2023 Financial Guidance | Record revenue of approximately $3,550,000 for the three months ended June 30, 2023; 65% increase over second quarter of 2022 |
| 06.07.2023 | gammaCore™ Selected for Study Funded by NFL and NFL Players Association on Alleviating Concussion Symptoms | Research grants jointly awarded to independent medical researchers studying alternative pain management treatments at American Society of Pain & Neuroscience and Emory University |
| 27.06.2023 | electroCore’s TAC-STIM™ Non-Invasive Vagal Nerve Stimulation Selected for Inclusion in the Air Force Research Laboratories Real-Time Assessing and Augmenting Cognitive Performance in Extreme Environme... | ROCKAWAY, N.J., June 27, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that its TAC-STIM non-invasive vagus nerve stimulation (“nVNS”) Human Perform... |
| 12.06.2023 | TriSalus Presents Additional Data for SD-101 Delivered by Proprietary PEDD™ Method with TriNav™ Device for Uveal Melanoma Liver Metastases at ASCO Annual Meeting | New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment and decreased circulating tumor DNA (ctDNA) levels |
| 26.05.2023 | electroCore, Inc. Announces Departure of JP Errico from the Board of Directors | ROCKAWAY, N.J., May 26, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the resignation of its Founder and former CEO, JP Errico from the Board of Dir... |
| 15.05.2023 | Exagen Inc. Reports First Quarter 2023 Results | Record Physician Demand for AVISE® CTD |
| 04.05.2023 | ATEC Reports First Quarter 2023 Financial Results | CARLSBAD, Calif.–(BUSINESS WIRE)–May 4, 2023– Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended Mar... |
| 03.05.2023 | electroCore Announces First Quarter 2023 Financial Results | Record first quarter 2023 net sales of $2.8 million, approximately 46% over first quarter 2022 |
| 26.04.2023 | National Institutes of Health Awards Grant for Pivotal Clinical Trial of gammaCore™ (nVNS) in Patients with Opioid Use Disorders | ROCKAWAY, N.J., April 26, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the National Institute on Drug Abuse (NIDA), part of the National Insti... |
| 24.04.2023 | Study Presented at 75th Annual Meeting of the American Academy of Neurology Demonstrates that gammaCore (nVNS) Can Accelerate Foreign Language Learning | Clinical trial (n=36) shows the ability of gammaCore (nVNS) to significantly improve the recall of a foreign language compared to sham while simultaneously showing improved focus and decreased fatigue in study participants |
| 20.04.2023 | TriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD™ Method in Stage IV Uveal Melanoma Patients With Liver Metastases | DENVER and FORT LAUDERDALE, Fla., April 20, 2023 – TriSalus Life Sciences® Inc., (“TriSalus” or the “Company”), an oncology company in the process of going public through a business combination transaction (the “Business Combination”) with ... |
| 20.04.2023 | Neurolens Measures Its One Millionth Patient | DALLAS, April 20, 2023 – Neurolens, a company commercializing innovative solutions to optimize vision, announced today that one million patients have been measured on the Neurolens Measurement Device, its cutting-edge eye tracking system th... |
| 19.04.2023 | ATEC Acquires Navigation-Enabled Robotics Platform; Raises 2023 Revenue Guidance on Strength of Preliminary First Quarter Revenue Results | CARLSBAD, Calif.–(BUSINESS WIRE)– Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it has acquired all assets related to the REMI Rob... |
| 19.04.2023 | ATEC Announces $60 Million Underwritten Offering | CARLSBAD, Calif.–(BUSINESS WIRE)– Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today the pricing of an underwritten registered offering of 4... |
| 17.04.2023 | electroCore Provides Select First Quarter 2023 Financial Guidance | ROCKAWAY, N.J., April 17, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today provided select preliminary unaudited financial guidance for the first... |
| 12.04.2023 | electroCore Expands Intellectual Patent Portfolio for nVNS Technology | electroCore Granted Three New U.S. Patents |
| 06.04.2023 | electroCore, Inc. Announces Product Registration in Indonesia, Malaysia and South Africa | ROCKAWAY, N.J., April 06, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the receipt of a license to import, distribute and market g... |
| 04.04.2023 | electroCore, Inc. Announces gammaCore Non-Invasive Vagus Nerve Stimulator Available Through the Carrick Institute | ROCKAWAY, N.J., April 04, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the gammaCore Sapphire™ non-invasive vagus nerve stimu... |
| 23.03.2023 | electroCore Reports Results of Pre-Clinical Trial in a Model of Traumatic Brain Injury | Pre-clinical trial demonstrates the ability of nVNS to decrease the amount of brain injury, decrease anxiety and improve motor function post injury |
| 21.03.2023 | electroCore’s Truvaga Users Reported Improved Stress, Anxiety, Sleep, Energy and Mood in Recent Focus Group Study | ROCKAWAY, N.J., March 21, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the results of a TruvagaTM focus group study conducted earl... |
| 20.03.2023 | Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results | Record AVISE® CTD Volume in 2022 |
| 08.03.2023 | electroCore Announces Fourth Quarter and Full Year 2022 Financial Results | Record full year 2022 net sales of $8.6 million increased 58% over $5.5 million for full year 2021 |
| 28.02.2023 | ATEC Reports Record Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Highlights | CARLSBAD, Calif.–(BUSINESS WIRE)– Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter and full year ended D... |
| 21.02.2023 | electroCore, Inc. Announces Exclusive Distribution Agreement with Byond Healthcare Pty Ltd, South Africa | ROCKAWAY, N.J., Feb. 21, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced an agreement with Byond Healthcare Pty Ltd. to serve as the ... |
| 21.02.2023 | TriSalus Life Sciences Appoints James Alecxih to Lead Device Technology Business | DENVER and CHICAGO, February 21, 2023 – TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”), an oncology company in the process of going public through a business combination transaction (the “Business Combination”) with MedTech Acq... |
| 16.02.2023 | electroCore Expands Intellectual Patent Portfolio for nVNS Technology | ROCKAWAY, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the United States Patent and Trademark Office (USPTO) has issued two pat... |
| 16.02.2023 | TriSalus Life Sciences Posts Updated Investor Presentation Highlighting Additional Phase 1 and 1b Clinical Data for Pressure-Enabled Regional Immuno-Oncology™-01 and -02 Studies | Data Further Supports the Potential of the Company’s Therapeutic Platform to Improve Immunotherapy Outcomes for Patients with Liver and Pancreatic Tumors |
| 14.02.2023 | electroCore Announces Reverse Stock Split | ROCKAWAY, N.J., Feb. 14, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced a planned reverse stock split of its shares of common stock a... |
| 23.01.2023 | Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors | SAN DIEGO, Jan. 23, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Tina S. Nova, Ph.D. has been elected as executive chair of the company’s board of directors, eff... |
| 17.01.2023 | electroCore Announces Expected Record 4Q 2022 Revenue of $2.5M; Provides Business Update | ROCKAWAY, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided select unaudited preliminary financial guidance for the fourth quarter and ... |
| 09.01.2023 | ATEC Announces Select Preliminary Financial 2022 Results, 2023 Guidance and Closing of Flexible, Non-Dilutive Debt Facility | CARLSBAD, Calif.–(BUSINESS WIRE)– Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today select preliminary financial results for the fourth qua... |
| 20.12.2022 | electroCore, Inc. Launches New Wellness Product Offering for Stress, Anxiety and Sleep | Truvaga™ handheld non-invasive vagus nerve stimulator offers drug-free 2-minute sessions |
| 15.12.2022 | TriSalus Life Sciences Highlights Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) Clinical Trial Progress and Pre-clinical Research Developments | Studies evaluating methods to overcome two major challenges in treating patients with liver and pancreatic tumors |
| 07.12.2022 | electroCore Announces Issuance of Two New U.S. Patents | Expansion of patent portfolio allows exploration of the role of nVNS beyond migraine and cluster headache |
| 20.11.2022 | TriSalus Life Sciences Provides Updates on Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) 01 and 02 Clinical Studies | Data further substantiates potential to significantly improve immunotherapy outcomes for patients with liver and pancreatic tumors |
| 18.11.2022 | gammaCore Sapphire™ Non-Invasive Vagus Nerve Stimulator (nVNS) Receives Unique National Product Code Number by the Belgian Pharmaceutical Association | ROCKAWAY, N.J., Nov. 18, 2022 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore Sapphire has been issued a National Code Number (CNK) in B... |
| 14.11.2022 | TriSalus Life Sciences to Become Publicly Traded Through Merger with MedTech Acquisition Corporation | Oncology Therapeutics Company Focused on Transforming Cancer Treatment with Proprietary Innovative Therapies and Disruptive Delivery Technology |
| 14.11.2022 | Exagen Inc. Reports Third Quarter 2022 Results | Medicare Reimbursement Returns |
| 03.11.2022 | electroCore Announces Third Quarter 2022 Financial Results | Third quarter 2022 revenue grew 33% over third quarter 2021 |
| 03.11.2022 | ATEC Reports Third Quarter 2022 Financial Results | CARLSBAD, Calif.–(BUSINESS WIRE)– Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended September 30, 2... |